Cessatech A/S

Cessatech A/S is a Danish pharmaceutical company focused on developing innovative, age-appropriate medications for children, specifically targeting pain management. They are a spin-out project from Rigshospitalet, Denmark's largest hospital, and their business model centers on identifying and developing drugs with a short time to market and low-risk profiles. The company's lead asset, CT001, is a nasal spray designed to provide pain relief for children aged 1-17 years, offering an alternative to potentially painful intravenous injections.

Cessatech is committed to addressing the significant unmet needs in pediatric medicine, particularly in the area of pain relief. They are actively working to secure regulatory approval for CT001 and have secured a commercialization agreement with Proveca Ltd for global distribution. Cessatech also has two other promising drug candidates in their pipeline, CT002 for MRI sedation and CT003, a local anesthetic gel, both aimed at improving pain management and reducing the need for invasive procedures in children.

Cessatech A/S is a Danish pharmaceutical company dedicated to rethinking child treatments. Driven by a mission to address the unmet need for safe and effective pain relief solutions specifically for children, Cessatech develops innovative, age-appropriate formulations for pain management, sedation, and wound care. They are committed to providing evidence-based treatments that improve the quality of care for children and minimize the need for invasive procedures, ultimately ensuring that children receive the best possible medical care.

Cessatech fosters a collaborative and driven culture focused on improving pediatric care. The company values innovation, evidenced-based practices, and a shared commitment to addressing the unmet needs of children in healthcare. Its mission and research inspire a sense of purpose and urgency among employees, who are passionate about developing safer and more effective treatments for young patients.